Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 4/20 | 0.58 |
| ▸ | MMP9 | P14780 | 3/20 | 0.58 |
| ▸ | MMP3 | P08254 | 1/20 | 0.58 |
| ▸ | MMP7 | P09237 | 1/20 | 0.58 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.54 |
| ▸ | MMP13 | P45452 | 4/20 | 0.52 |
| ▸ | LIPE | Q05469 | 1/20 | 0.48 |
| ▸ | ABHD6 | Q9BV23 | 2/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.46 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.46 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL309347 | 1.00 | MMP1 (0.58) | MMP1MMP9MMP3MMP7HSD11B1 | |
| SCHEMBL2441138 | 0.88 | MMP1 (0.63) | MMP1MMP9MMP3MMP7HSD11B1 | |
| SCHEMBL309055 | 0.87 | MMP1 (0.55) | MMP1MMP9MMP3MMP7HSD11B1 | |
| SCHEMBL309795 | 0.87 | MMP1 (0.55) | MMP1MMP9MMP3MMP7HSD11B1 | |
| SCHEMBL3704136 | 0.87 | HSD11B1 (0.58) | MMP1MMP9MMP3MMP7HSD11B1 | |
| SCHEMBL3696020 | 0.87 | HSD11B1 (0.58) | MMP1MMP9MMP3MMP7HSD11B1 | |
| SCHEMBL1947519 | 0.84 | MMP1 (0.57) | MMP1MMP9MMP3MMP7HSD11B1 | |
| SCHEMBL7889219 | 0.84 | MMP1 (0.57) | MMP1MMP9MMP3MMP7HSD11B1 | |
| SCHEMBL27727372 | 0.84 | MMP1 (0.56) | MMP1MMP9MMP3MMP7HSD11B1 | |
| SCHEMBL763825 | 0.84 | HSD11B1 (0.60) | MMP1MMP9MMP3MMP7HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8093249-B2 | Pyrazolo[1,5-A]pyrimidine-carbonyl-piperazine derivatives | Convergence Pharmaceuticals Limited (GB) | 2012-01-10 | — | — | US | disclosed |
| US-20100016330-A1 | Novel Derivatives | Convergence Pharmaceuticals Limited (GB) | 2010-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016330-A1 | Novel Derivatives | CACNB2, CACNA1B, CACNA1D | MMP1 4589/4885MMP9 4777/4885MMP3 4534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.